Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Hackshaw

Showing results (41-50 of 166) with videos related to

Pageof 17
Sort By:
Journal of the Royal Society of Medicine|June 3, 2008
Setting up non-commercial clinical trials takes too long in the UK: findings from a prospective studyAllan Hackshaw, Hannah Farrant, Sue Bulley, et al.
The Lancet. Oncology|November 30, 2020
The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysisJames J Clark, Dominic Dwyer, Nina Pinwill, et al.
The Lancet. Diabetes & Endocrinology|December 4, 2018
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trialHakim-Moulay Dehbi, Ujjal Mallick, Jonathan Wadsley, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2007
Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancerSiow Ming Lee, Lindsay James, Tomas Buchler, et al.
International Journal of Cancer|March 16, 2017
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysisZuyao Yang, Allan Hackshaw, Qi Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancerAllan Hackshaw, Michael Roughton, Sharon Forsyth, et al.
Cancer Medicine|March 17, 2025
Estimating the Burden of False Positives and Implementation Costs From Adding Multiple Single Cancer Tests or a Single Multi-Cancer Test to Standard-Of-Care ScreeningSarina Madhavan, Allan Hackshaw, Earl Hubbell, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|January 15, 2015
Improving research on the efficacy, effectiveness, and harms of traditional chinese medicineJin-Ling Tang, Allan Hackshaw, Li-Xing Lao, et al.
Thorax|November 23, 2011
Attitudes to participation in a lung cancer screening trial: a qualitative studyDeesha Patel, Ajiri Akporobaro, Nyasha Chinyanganya, et al.
British Journal of Cancer|August 24, 2021
Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UKAllan Hackshaw, Sarah S Cohen, Heidi Reichert, et al.
Pageof 17

Showing results (41-50 of 166) with videos related to

Sort By:
Pageof 17
Journal of the Royal Society of Medicine|June 3, 2008
Setting up non-commercial clinical trials takes too long in the UK: findings from a prospective studyAllan Hackshaw, Hannah Farrant, Sue Bulley, et al.
The Lancet. Oncology|November 30, 2020
The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysisJames J Clark, Dominic Dwyer, Nina Pinwill, et al.
The Lancet. Diabetes & Endocrinology|December 4, 2018
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trialHakim-Moulay Dehbi, Ujjal Mallick, Jonathan Wadsley, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2007
Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancerSiow Ming Lee, Lindsay James, Tomas Buchler, et al.
International Journal of Cancer|March 16, 2017
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysisZuyao Yang, Allan Hackshaw, Qi Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancerAllan Hackshaw, Michael Roughton, Sharon Forsyth, et al.
Cancer Medicine|March 17, 2025
Estimating the Burden of False Positives and Implementation Costs From Adding Multiple Single Cancer Tests or a Single Multi-Cancer Test to Standard-Of-Care ScreeningSarina Madhavan, Allan Hackshaw, Earl Hubbell, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|January 15, 2015
Improving research on the efficacy, effectiveness, and harms of traditional chinese medicineJin-Ling Tang, Allan Hackshaw, Li-Xing Lao, et al.
Thorax|November 23, 2011
Attitudes to participation in a lung cancer screening trial: a qualitative studyDeesha Patel, Ajiri Akporobaro, Nyasha Chinyanganya, et al.
British Journal of Cancer|August 24, 2021
Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UKAllan Hackshaw, Sarah S Cohen, Heidi Reichert, et al.
Pageof 17